Joseph Ross, MD, MHS
Professor of Medicine (General Medicine) and of Public Health (Health Policy and Management)Cards
Contact Info
General Internal Medicine
P.O. Box 208093
New Haven, CT 06520-8093
United States
Education
Yale School of Medicine (2006)
Albert Einstein College of Medicine (2001)
University of Rochester (1996)
Training
Montefiore Medical Center (2004)
Montefiore Medical Center/Albert Einstein College of Medicine (2004)
Montefiore Medical Center/Albert Einstein College of Medicine (2004)
Contact Info
General Internal Medicine
P.O. Box 208093
New Haven, CT 06520-8093
United States
Education
Yale School of Medicine (2006)
Albert Einstein College of Medicine (2001)
University of Rochester (1996)
Training
Montefiore Medical Center (2004)
Montefiore Medical Center/Albert Einstein College of Medicine (2004)
Montefiore Medical Center/Albert Einstein College of Medicine (2004)
Contact Info
General Internal Medicine
P.O. Box 208093
New Haven, CT 06520-8093
United States
Education
Yale School of Medicine (2006)
Albert Einstein College of Medicine (2001)
University of Rochester (1996)
Training
Montefiore Medical Center (2004)
Montefiore Medical Center/Albert Einstein College of Medicine (2004)
Montefiore Medical Center/Albert Einstein College of Medicine (2004)
About
Copy Link
Titles
Professor of Medicine (General Medicine) and of Public Health (Health Policy and Management)
Biography
Joseph S. Ross, MD, MHS, is a Professor of Medicine (General Medicine) and of Public Health (Health Policy and Management), a member of the Center for Outcomes Research and Evaluation (CORE) at the Yale-New Haven Hospital, and an Co-Director of the National Clinician Scholars program (NCSP) at Yale. He completed his undergraduate degrees in biological science: neuroscience and psychology at the University of Rochester and his medical degree at the Albert Einstein College of Medicine, Bronx, NY. After completing his post-graduate training in primary care internal medicine at Montefiore Medical Center in Bronx, NY, Dr. Ross was a fellow in the Robert Wood Johnson Foundation Clinical Scholars program at Yale, earning a Master’s degree in health sciences research. Using health services research methods, Dr. Ross’s research focuses on examining factors which affect the use or delivery of recommended ambulatory care services for older adults and other vulnerable populations, evaluating the impact of state and federal policies on the delivery of appropriate and higher quality care, and addressing issues related to pharmaceutical and medical device regulation, evidence development, postmarket surveillance, and clinical adoption. In addition, he collaborates with a multi-disciplinary team of investigators under contract for the Centers for Medicare and Medicaid Services to develop statistical models that are used to measure and publicly report hospital and ambulatory care clinical outcomes using administrative data. Dr. Ross co-directs the Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI), the Yale Open Data Access (YODA) Project, the Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT) at Yale Law School, and leads efforts at Yale-New Haven Health System in collaboration with the National Evaluation System for health Technology. Dr. Ross is currently a Deputy Editor at JAMA, co-founder of medRxiv, Chair of the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC), and a member of the New England Comparative Effectiveness Public Advisory Council (New England CEPAC) for ICER.
Appointments
General Internal Medicine
ProfessorPrimaryHealth Policy & Management
ProfessorSecondaryInstitution for Social and Policy Studies
ProfessorSecondary
Other Departments & Organizations
- All Institutions
- Cancer Prevention and Control
- Center for Outcomes Research & Evaluation (CORE)
- Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT)
- General Internal Medicine
- Health Policy & Management
- Institution for Social and Policy Studies
- Internal Medicine
- National Clinician Scholars Program
- Regulatory Affairs Track
- Yale New Haven Health System
- Yale School of Public Health
- Yale Ventures
Education & Training
- MHS
- Yale School of Medicine (2006)
- Postgraduate Training
- Montefiore Medical Center (2004)
- Residency
- Montefiore Medical Center/Albert Einstein College of Medicine (2004)
- Internship
- Montefiore Medical Center/Albert Einstein College of Medicine (2004)
- MD
- Albert Einstein College of Medicine (2001)
- BS
- University of Rochester (1996)
- BA
- University of Rochester (1996)
Research
Copy Link
Overview
Medical Research Interests
Public Health Interests
ORCID
0000-0002-9218-3320
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Harlan Krumholz, MD, SM
Reshma Ramachandran, MD, MPP, MHS
Jeph Herrin, PhD
Jennifer E Miller, PhD
Cary P Gross, MD
Jeptha Curtis, MD
Quality of Health Care
Delivery of Health Care
Health Services Research
Publications
2026
Pharmaceutical Manufacturer Kickback Resolutions and Associated Financial Penalties, 2000-2025
Liu T, Ross J, Morten C, Ramachandran R. Pharmaceutical Manufacturer Kickback Resolutions and Associated Financial Penalties, 2000-2025. JAMA Network Open 2026, 9: e261735. PMID: 41823969, PMCID: PMC12988444, DOI: 10.1001/jamanetworkopen.2026.1735.Peer-Reviewed Original ResearchAltmetricCommercial Price Variation for Outpatient Physical Therapy Services
Ranando M, Wallach J, Ross J, Skydel J. Commercial Price Variation for Outpatient Physical Therapy Services. JAMA Internal Medicine 2026, 186 PMID: 41770572, PMCID: PMC12954591, DOI: 10.1001/jamainternmed.2025.8355.Peer-Reviewed Original ResearchAltmetricFDA approval of benzgalantamine exposes flaws in the 505(b)(2) pathway for innovations on existing drugs
Reddy N, Steinman M, Ross J, Widera E, Zeldes N, Steinbrook R, Ramachandran R. FDA approval of benzgalantamine exposes flaws in the 505(b)(2) pathway for innovations on existing drugs. BMJ Evidence-Based Medicine 2026, bmjebm-2025-114142. PMID: 41771551, DOI: 10.1136/bmjebm-2025-114142.Peer-Reviewed Original ResearchAltmetricGLP-1 Receptor Agonist Prescriptions for Adolescents With Obesity and Associated Disparities
Kim C, Sharifi M, Ross J, Chen Y, Xu H, Krumholz H, Lu Y. GLP-1 Receptor Agonist Prescriptions for Adolescents With Obesity and Associated Disparities. JAMA Pediatrics 2026, 180: 334-336. PMID: 41557442, PMCID: PMC12820773, DOI: 10.1001/jamapediatrics.2025.5708.Peer-Reviewed Original ResearchAltmetricModeling In-Hospital Mortality Among Patients Undergoing Percutaneous Coronary Intervention with Acute Myocardial Infarction Complicated by Cardiogenic Shock Receiving Mechanical Circulatory Support
Hurley N, Mortazavi B, Dhruva S, Ross J, Ngufor C, Curtis J, Krumholz H, Desai N. Modeling In-Hospital Mortality Among Patients Undergoing Percutaneous Coronary Intervention with Acute Myocardial Infarction Complicated by Cardiogenic Shock Receiving Mechanical Circulatory Support. Medical Devices Evidence And Research 2026, 19: 585943. PMID: 41804390, PMCID: PMC12967445, DOI: 10.2147/mder.s585943.Peer-Reviewed Original ResearchAltmetricConceptsMortality riskAssociated with higher mortality riskNational Cardiovascular Data RegistryAssociated with lower riskIntra-aortic balloon pumpHigher systolic blood pressureHigher mortality riskHeterogeneity of treatment effectsRisk of mortalityPercutaneous coronary interventionAssociated with usePatient visitsHigher RatesIn-Hospital MortalitySystolic blood pressureAcute myocardial infarctionData registryAMI-CSCoronary interventionMortality effectsMyocardial infarction complicationsIn-HospitalImpella deviceLow riskAcute myocardial infarction complicationsTherapeutic Benefit Ratings for FDA Breakthrough-Designated Devices
Kadakia K, Swoboda C, Moneer O, Dhruva S, Ross J, Krumholz H, Burke J, Rathi V. Therapeutic Benefit Ratings for FDA Breakthrough-Designated Devices. JAMA Surgery 2026, 161 PMID: 41739483, PMCID: PMC12936964, DOI: 10.1001/jamasurg.2025.6859.Peer-Reviewed Original ResearchAltmetricAI Use in Research and the Need for Continued Guidance
Malani P, Ross J. AI Use in Research and the Need for Continued Guidance. JAMA: The Journal Of The American Medical Association 2026, 335: 673-673. PMID: 41604205, DOI: 10.1001/jama.2025.26845.Peer-Reviewed Original ResearchAltmetricPremarket and postmarket real-world evidence studies supporting U.S. Food and Drug Administration regulatory decision-making, 2016-2024.
Li L, Ramachandran R, Ross J, Wallach J. Premarket and postmarket real-world evidence studies supporting U.S. Food and Drug Administration regulatory decision-making, 2016-2024. Clinical Trials 2026, 17407745251415190. PMID: 41641793, PMCID: PMC12900038, DOI: 10.1177/17407745251415190.Peer-Reviewed Original ResearchAltmetricConceptsFood and Drug AdministrationU.S. Food and Drug AdministrationReal-world dataReal-world evidence studiesElectronic health recordsDrug AdministrationEvidence studiesElectronic healthNovel therapeuticsHealth recordsData sourcesStudy designNon-interventionalDeterminants of effectivenessReview documentsAdministrative claims dataMedical recordsPatient RegistryLower Extremity Complications in Adults with Type 2 Diabetes treated with GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas: An Emulated Target Trial
McCoy R, Swarna K, Polley E, Deng Y, Chawla S, Neumiller J, Galindo R, Umpierrez G, Ross J, Mickelson M, Herrin J. Lower Extremity Complications in Adults with Type 2 Diabetes treated with GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas: An Emulated Target Trial. Endocrine Practice 2026 PMID: 41638310, DOI: 10.1016/j.eprac.2026.01.012.Peer-Reviewed Original ResearchConceptsLower extremity complicationsExtremity complicationsDipeptidyl peptidase-4 inhibitorsSodium-glucose cotransporter 2 inhibitorsIntention-to-treat frameworkMedication classesSulfonylurea useHealth care costsDiabetes management teamGLP-1RACardiovascular riskHigh riskLower extremity morbidityCox proportional hazards modelsSGLT2i useTarget trialsModerate cardiovascular riskComposite outcomeGlucose-lowering medicationsProportional hazards modelAmputation eventsCare costsNational claims databaseReceptor agonistsType 2 diabetesPostmarket Drug Safety−Related Actions Before and After the US Food and Drug Administration Amendments Act
Doernberg H, Wallach J, Jeffery M, Mooghali M, Ramachandran R, Ross J. Postmarket Drug Safety−Related Actions Before and After the US Food and Drug Administration Amendments Act. JAMA Internal Medicine 2026, 186: 233-242. PMID: 41359349, PMCID: PMC12687201, DOI: 10.1001/jamainternmed.2025.6566.Peer-Reviewed Original ResearchAltmetric
Academic Achievements & Community Involvement
Copy Link
Activities
activity JAMA
06/01/2023 - PresentJournal ServiceDeputy Editoractivity BMJ
2020 - 2023Journal ServiceAssociate Editoractivity JAMA Internal Medicine
04/01/2013 - 12/31/2019Journal ServiceAssociate Editoractivity Journal of General Internal Medicine
2011 - 2013Journal ServiceDeputy Editor
News
Copy Link
News
- March 05, 2026Source: Yale News
Cost of Physical Therapy Varies Widely from State-to-State
- November 03, 2025Source: JAMA
Dean Megan Ranney contributes to new report aimed at reducing firearm violence
- October 21, 2025Source: Yale News
IV Hydration Spas Lack Adequate Oversight, Study Finds
- September 18, 2025Source: U.S. News & World Report
Pharma Payments Might Influence MS Drug Prescriptions, Researchers Argue
Get In Touch
Copy Link
Contacts
General Internal Medicine
P.O. Box 208093
New Haven, CT 06520-8093
United States
Locations
E.S. Harkness Memorial Hall, Building A
Academic Office
367 Cedar Street, Ste 405B
New Haven, CT 06510